Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ahmad Al-Hindi

Cardiovascular Disease Jonesboro, AR Medical Doctor

NPI 1851324446 CMS profile 501306

201 E Oak Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$2,349

97 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ahmad Al-Hindi of Jonesboro, AR is reported in the CMS Open Payments database as having received $2,349 across 97 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $319 12
2024 General $367 16
2023 General $475 10
2022 General $307 12
2021 General $201 11
2020 General $186 9
2019 General $494 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ahmad Al-Hindi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ahmad Al-Hindi were reported at $319. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ahmad Al-Hindi Cardiovascular Disease median Middle half National median
2019 $494 $450 $127–$1,392 $163
2020 $186 $242 $77–$751 $114
2021 $201 $335 $101–$1,037 $132
2022 $307 $395 $121–$1,211 $149
2023 $475 $443 $136–$1,283 $160
2024 $367 $450 $136–$1,323 $164
2025 $319 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $546 27 payments
  2. Abiomed $197 4 payments
  3. Amgen Inc. $193 12 payments
  4. Novartis Pharmaceuticals Corporation $185 11 payments
  5. Medtronic, Inc. $153 4 payments
  6. Edwards Lifesciences Corporation $147 2 payments
  7. Abbott Laboratories $124 6 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $124 2 payments
  9. AstraZeneca Pharmaceuticals LP $106 2 payments
  10. Pfizer Inc. $102 4 payments
  11. Other $472 23 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,349 97 payments
Products named General payments · program years 2019–2025
  1. Repatha $193 12 payments
  2. Impella $176 3 payments
  3. ENTRESTO $173 10 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $147 2 payments
  5. JARDIANCE $124 2 payments
  6. FARXIGA $106 2 payments
  7. Corlanor $105 7 payments
  8. General - Stents $101 1 payment
  9. XARELTO $99 5 payments
  10. PULSESELECT $93 2 payments
  11. Other $1,158 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

6,160

Median for Internal Medicine: 777

Drug cost

$817,196

Median for Internal Medicine: $73,373

Branded share of claims

32.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 324 $234,111
Jardiance Empagliflozin Brand 157 $135,875
Entresto Sacubitril/Valsartan Brand 151 $133,351
Repatha Sureclick Evolocumab Brand 79 $118,193
Xarelto Rivaroxaban Brand 56 $38,735
Vascepa Icosapent Ethyl Brand 96 $36,817
Farxiga Dapagliflozin Propanediol Brand 39 $36,496
Praluent Pen Alirocumab Brand 18 $22,437
Atorvastatin Calcium Generic 955 $9,561
Ezetimibe Generic 410 $8,260

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$173,644

Medicare's payments for the services billed

Medicare patients

2,423

Average age 75

Services billed

5,268

1,276 women, 1,147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 58%
Arthritis 55%
Atrial fibrillation 47%
Diabetes 45%
Heart failure 41%
Chronic kidney disease 32%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $89
$89 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

97 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record